about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Q&A: JP Mor­gan’s new life sci­ences pri­vate cap­i­tal leader on the bank’s ex­pand­ing am­bi­tions, vet­ting star­tups and ...

Last year
People
Financing

Up­dat­ed: Meta­bol­ic drug de­vel­op­er High­T­ide Ther­a­peu­tics eyes $36M raise with HK IPO

Last year
Financing

FDA puts three CARs­gen CAR-T ther­a­pies on clin­i­cal hold, in­clud­ing Mod­er­na-part­nered pro­gram

Last year
Cell/Gene Tx
FDA+

Icosavax buy­out caps As­traZeneca’s long search for a vac­cine plat­form

Last year
Deals
Pharma

As­traZeneca plunks down $800M+ up­front to buy vac­cine de­vel­op­er Icosavax and chal­lenge Pfiz­er, GSK in RSV

Last year
Deals

Af­fimed nar­rows PhI/IIa fo­cus; Bris­tol My­ers pays Agenus $25M; Mer­ck, Mod­er­na start an­oth­er PhI­II can­cer vac­cine

Last year
News Briefing

Ab­b­Vie’s $8.7B neu­ro gam­bit; Land­mark sick­le cell ap­provals; Roche buys a GLP-1 com­pa­ny; End­points 100 biotech ...

Last year
Weekly

Lian­Bio re­jects Con­cen­tra bid; Tread­well cuts work­ers; As­traZeneca inks CAR-T deal

Last year
News Briefing

Mer­ck de­tails PhII TIG­IT/PD-1 fail in lung can­cer

Last year
R&D

FDA’s CAR-T safe­ty probe; Ab­b­Vie’s $10B ADC wa­ger; Pfiz­er’s GLP-1 set­back; Ace­lyrin’s CRO dra­ma; and more

Last year
Weekly

Small transpa­cif­ic team led by Lil­ly, Ever­est vet turns to com­pu­ta­tion­al tools for next wave of pep­tide drug ...

Last year
Financing
Startups

Luke Miels sheds light on GSK in­ter­nal changes, ‘very busy’ BD scene

Last year
Pharma

Eli Lil­ly’s Dan Skovron­sky on oral GLP-1, ‘slow­er ramp’ for Alzheimer’s and deals on ‘un­der­ap­pre­ci­at­ed’ ...

Last year
People
R&D

Im­muno­vant takes on ar­genx, J&J with plans to test FcRn in­hibitor in mul­ti­ple par­al­lel tri­als af­ter PhI win 

Last year
R&D

For­mer Terns CEO Senthil Sun­daram pass­es away fol­low­ing bat­tle with can­cer

Last year
People

Mer­ck­'s neu­ro-in­spired buy­out; Bay­er's bad week; One launch, one shut­down for Flag­ship; and more

Last year
Weekly

Up­dat­ed: Mer­ck com­mits up to $610M to buy out pre­clin­i­cal biotech and its neu­rode­gen­er­a­tive dis­ease work

Last year
Deals

Mor­phoSys march­es ahead with plans to file myelofi­bro­sis drug de­spite mixed PhI­II re­sults

Last year
R&D

'In­fe­ri­or ef­fi­ca­cy' leads to pre­ma­ture end of PhI­II for Bay­er's next-gen blood thin­ner asun­dex­i­an

Last year
R&D

Land­mark CRISPR ap­proval; Why don't in­vestors like Verve’s base edit­ing da­ta?; Janet Wood­cock to re­tire; Late ...

Last year
Weekly

As­traZeneca lands FDA ap­proval for AKT in­hibitor in bio­mark­er-de­fined breast can­cer sub­set

Last year
Pharma
FDA+

Q&A: Can on­colyt­ic virus­es make a come­back? Ex­perts dis­sect clin­i­cal fail­ures and out­line path for­ward

Last year
R&D

In a world first, Ver­tex, CRISPR win UK ap­proval for CRISPR-edit­ed ther­a­py to treat sick­le cell dis­ease, ...

Last year
Cell/Gene Tx
FDA+

Astel­las bags prostate can­cer drug in $175M buy­out as Xtan­di ap­proach­es patent cliff

Last year
Deals
First page Previous page 45678910 Next page Last page
A service from the Financial Times